A multisite registry study involving 5000 US patients showed that clinicians often don’t treat patients with atherosclerotic cardiovascular disease according to recommendations for intensive medication if low-density lipoprotein cholesterol (LDL-C) levels are 70 mg/dL or more.
The patients were enrolled in 1 of 3 cohorts between December 2016 and July 2018. One group already received a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i). The other 2 groups, which didn’t receive a PCSK9i, had LDL-C levels of 70 to 99 mg/dL or 100 mg/dL or more.
Slomski A. Guidelines for Lipid-Lowering Therapy Intensification Rarely Followed. JAMA. 2021;326(9):800. doi:10.1001/jama.2021.14709
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: